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Aims High-density lipoprotein (HDL) has been reported to have cardioprotective properties independent
from its cholesterol transport activity. The influence of native HDL and reconstituted HDL (rHDL) on
Stat3, the transcription factor playing an important role in myocardium adaptation to stress, was ana-
lysed in neonatal rat ventricular cardiomyocytes. We have investigated modulating the composition of
rHDL as a means of expanding its function and potential cardioprotective effects.
Methods and results Stat3 phosphorylation and activation were determined by western blotting and
electrophoretic mobility shift assay (EMSA). In ventricular cardiomyocytes, HDL and the HDL constituent
sphingosine-1-phosphate (S1P) induce a concentration- and time-dependent increase in Stat3 acti-
vation. They also enhance extracellular signal-regulated kinases (ERK1/2) and p38 mitogen-activated
protein kinase (MAPK) phosphorylation. U0126, a specific inhibitor of MEK1/2, the upstream activator
of ERK1/2, abolishes HDL- and S1P-induced Stat3 activation, whereas the p38 MAPK blocker SB203580
has no significant effect. Inhibition of the tyrosine kinase family Src (Src) caused a significant reduction
of Stat3 activation, whereas inhibition of phosphatidylinositol 3-kinase (PI3K) had no effect. S1P and
rHDL containing S1P have a similar strong stimulatory action on Stat3, ERK1/2, and p38 MAPK compar-
able to native HDL. S1P-free rHDL has a much weaker effect. Experiments with agonists and antagonists
of the S1P receptor subtypes indicate that HDL and S1P activate Stat3 mainly through the S1P2 receptor.
Conclusion In ventricular cardiomyocytes, addition of S1P to rHDL enhances its therapeutic potential by
improving its capacity to activate Stat3. Activation of Stat3 occurs mainly via the S1P constituent and
the lipid receptor S1P2 requiring stimulation of ERK1/2 and Src but not p38 MAPK or PI3K. The study








High-density lipoprotein (HDL) is known to remove choles-
terol from peripheral tissues in a process known as reverse
cholesterol transport. Beyond this function, HDL has been
shown to exert cardiovascular protective effects in endo-
thelial and vascular smooth muscle cells by generating a
cascade of intracellular signals including the activation of
PI3K/Akt, ERK1/2, p38 mitogen-activated protein kinase
(MAPK), and RhoA.1–3
Several studies have demonstrated that reconstituted HDL
(rHDL) represents an important therapeutic potential
against cardiovascular disease.4–6 rHDL typically consists of
the apolipoprotein (apo) AI and phospholipids. A recent
innovation has been to complement rHDL with other bio-
active molecules that can extend its physiological impact.
Matsuo et al.6 developed a novel rHDL containing apoAI,
phosphatidylcholine, and sphingosine-1-phosphate (S1P)
which has been shown to play a major role in HDL-induced
cellular signalling.2 This rHDL exerted S1P-mediated stimu-
latory effects on cell proliferation and tube formation in
endothelial cells.6
There is little information concerning a direct protective
effect of HDL or rHDL on the heart. Calabresi et al.7
showed that HDL protects isolated rat hearts from ischae-
mia/reperfusion (I/R) injury by reducing the ischaemia-
induced cardiac tumour necrosis factor-a expression.
Recently, Theilmeier et al.8 demonstrated that native,
human HDL, and its sphingolipid component, S1P, protect
the heart against I/R injury in vivo.
Surprisingly, there is no information concerning HDL-
induced activation of the signal transducer and activator of
transcription 3 (Stat3), despite growing evidence that Stat3
plays an important role in cardiac remodelling. Multiple* Corresponding author. Tel: þ41 22 3729303; fax: þ41 22 3729329.
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studies have shown that the activation of Stat3 promotes car-
diomyocyte survival and hypertrophy, as well as cardiac angio-
genesis, indicating that Stat3 is beneficial for the heart.9,10
During its activation Stat3 acquires an obligatory tyrosine
phosphorylation11 as well as serine phosphorylation which
appears to be in some cases necessary for maximal transcrip-
tional activity of Stat3,12 while inhibitory in others.13
If rHDL is to be tailored to particular clinical effects, it is
important to attribute these effects to the added molecules
and define the regulatory pathways involved. In the present
work, we investigated the activation of Stat3 by HDL iso-
lated from human plasma and by rHDL containing S1P and/
or apoAI in neonatal rat ventricular cardiomyocytes. More-
over, we studied the involvement of ERK1/2, p38 MAPK,
tyrosine kinase family Src (Src), PI3K, Rho-associated
kinase (ROCK), phospholipase C (PLC), and protein kinase
C (PKC) in HDL-induced Stat3 activation.
2. Methods
A detailed description of Methods is available at Cardiovascular
Research online.
2.1 Cell culture
This investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by US National Institues of Health
(NIH Publication No. 85-23, revised 1966). It was also approved by
the Office Ve´te´rinaire Fe´de´ral and Cantonal, Geneva, Switzerland.
Neonatal cardiomyocytes were isolated from 1-to-2-day-old Wistar
rats ventricles by digestion with trypsin-EDTA and type 2 collagenase
as we have previously described.14 Cardiomyocytes were used on the
third day of culture, after 16–20 h in DMEM medium depleted in FCS.
2.2 Western blotting
After stimulation, cells were washed with PBS and lysed. Total cell
proteins were separated by SDS–PAGE and blotted onto nitrocellu-
lose membrane. Afterwards, membranes were probed with specific
antibodies against phosphorylated Stat3, ERK1/2, p38 MAPK, and Src
and reprobed with antibodies against total Stat3, p38 MAPK, or Src.
Specific bands were visualized with a chemiluminescence kit.
2.3 Electrophoretic mobility shift assay
Nuclear extracts were prepared and electrophoretic mobility shift
assay performed as previously described.14 To specify Stat3-SIE
(sis-inducible element) DNA binding, polyclonal anti-Stat3 antibody
or anti-Stat1 antibody were added to the reaction mixture contain-
ing the labelled probe. To confirm the specificity of the labelled SIE
DNA probe, competition assay was performed using unlabelled SIE
DNA sequence.
2.4 Preparation of HDL and of reconstituted HDL
HDL (d ¼ 1.063–1.21 g/mL) was isolated by cumulative flotation
ultracentrifugation according to James et al.15 from a plasma pool
provided by healthy volunteers. Three different forms of rHDL
were prepared by the cholate dialysis procedure.16 rHDL A con-
tained phospholipids and S1P; rHDL B contained phospholipids, S1P
and apoAI; rHDL C contained phospholipids and apoAI. For prep-
arations B and C, the phospholipid:apoAI molar ratio was 100:1.
2.5 Statistical analysis
All values are expressed as mean+ SEM. Differences between
groups were determined using either two-tailed unpaired Student’s
t-tests or one-way ANOVA, followed by Bonferroni’s post-hoc test
where applicable. P , 0.05 was accepted as statistically significant.
3. Results
3.1 HDL and sphingosine-1-phosphate induce a
time- and concentration-dependent serine and
tyrosine phosphorylation of Stat3
The activation of Stat3 by HDL and its constituent S1P was first
investigated by measuring Stat3 phosphorylation on tyrosine
and serine residues in ventricular cardiomyocytes by western
blotting. As shown in Figure 1A, HDL (400 mg protein/mL), cor-
responding to physiological extravascular concentrations,17
induces Stat3 phosphorylation on tyrosine 705 as well as on
serine 727 in a time-dependent manner. It promoted a signifi-
cant serine phosphorylation within 3 min, reaching maximal
values after 30 min. In contrast, tyrosine phosphorylation
occurred only 1 h after exposition of cardiomyocytes to HDL.
Both serine and tyrosine phosphorylation levels were sustained
during 1–3 h of stimulation with HDL. The kinetics of
S1P-induced Stat3 serine and tyrosine phosphorylation were
very similar to those of HDL-induced responses (Figure 1C).
The HDL- and S1P-induced increase in Stat3 phosphorylation
wasalso found tobeconcentration-dependent,with significant
responsesobservedafter 90 minof stimulationwith 100 mg/mL
of HDL (Figure 1B) and with 100 nM of S1P (Figure 1D).
3.2 Effect of HDL, sphingosine-1-phosphate,
and different reconstituted HDL on Stat3
phosphorylation and on Stat3 DNA-binding
To investigate the specific roleof theHDLconstituents, S1Pand
apoAI in HDL-induced Stat3 phosphorylation, we stimulated
cells with three different rHDLs, containing, respectively,
S1P alone (rHDL A), S1PþapoAI (rHDL B), and apoAI (rHDL C).
We used two concentrations: 1 mM S1P and/or 20 mg/mL
apoAI, and 5 mM S1P and/or 100 mg/mL apoAI. Cells were
also stimulated with native, human HDL (400 mg/mL) and
S1P (1 mM). As illustrated in Figure 2A, the two rHDLs (rHDL
A and rHDL B) containing S1P (1 mM) increased serine and tyro-
sine phosphorylation of Stat3 in the same way as HDL and S1P.
rHDL containing higher concentrations of S1P (5 mM) did not
significantly augment the responses obtained with the lower
concentration. In contrast, rHDL C which contained only
apoAI had a significantly weaker effect on Stat3 phosphoryl-
ation. Consistently, rHDL B containing S1P and apoAI induced
the same response as HDL A containing only S1P.
Figure 2B illustrates the Stat3 DNA-binding induced by
rHDL, HDL, and S1P. Cells were incubated for 90 min with
HDL (400 mg/mL), S1P (1 and 5 mM), and the three rHDL prep-
arations (1 mM S1P, 1 mM S1Pþ20 mg/mL apoAI, and 20 mg/mL
apoAI). As shown, 90 min of stimulation with HDL or S1P
strongly enhanced the SIE DNA-binding of Stat3. In contrast,
5 min of stimulation with HDL or S1P had no effect on the
Stat3 DNA-binding (data not shown). As for Stat3 phosphoryl-
ation, S1P and the two rHDLs containing S1P (rHDL A and B)
markedly increased Stat3 DNA-binding, whereas rHDL C con-
taining only apoAI had a considerably weaker effect.
As shown in Figure 2B, the specificity of the Stat3/SIE DNA
complex is demonstrated by the disappearance of this
complex in the presence of anti-Stat3 antibody. In contrast,
the anti-Stat1 antibody had no effect, confirming specific
Stat3 binding upon HDL stimulation. During competition assay
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Figure 1 HDL and S1P induce an increase in Stat3 phosphorylation on tyrosine 705 and serine 727. (A and C) Time-dependent increase in Stat3 phosphorylation
on tyrosine 705 and serine 727 induced by HDL (A, 400 mg/mL) and S1P (C, 1 mM), compared with unstimulated cardiomyocytes (control). (B and D) Cells were
stimulated for 90 min with increasing concentrations of HDL (B, 100–800 mg/mL) or S1P (D, 0.1–5 mM). (A–D) Stat3 phosphorylation on tyrosine 705 (Stat3-tyr-P)
and serine 727 (Stat3-ser-P) was detected by western blotting; protein loading was assessed by total Stat3. Specific bands corresponding to phosphorylated Stat3
were quantified by densitometry and expressed as percentage of the control. *P , 0.05 compared with control values (n ¼ 3–4).
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with a 100-fold excess of unlabelled SIE DNA (cold probe), the
band corresponding to the binding of Stat3 to the SIE sequence
disappeared, confirming the specificity of SIE DNA binding.
Our results indicate that HDL activates Stat3 mainly via its
sphingolipid constituent S1P.
3.3 HDL and sphingosine-1-phosphate induce
Stat3 phosphorylation via the S1P2 receptor
To determine which S1P receptors are involved in the Stat3
phosphorylation induced by HDL and S1P, we used several
agonists and antagonists of the S1P receptors S1P1–S1P5.18–
20 We found that the presence of the highly selective S1P2
antagonist, JTE013,18 abolished the ability of S1P to induce
Stat3 serine and tyrosine phosphorylation, and significantly
inhibited that of HDL (Figure 3A). In contrast, incubation of
cardiomyocytes with SEW2871, an S1P1 receptor-specific
agonist, and FTY720, a high-affinity agonist of S1P1, S1P3,
S1P4, and S1P5 receptors, did not induce Stat3 phosphoryl-
ation, neither on serine nor on tyrosine (Figure 3B). Neither
did VPC23019, a competitive antagonist of the S1P1/S1P3
receptors,20 significantly affect HDL- and S1P-induced Stat3
phosphorylation (Figure 3C). Interestingly, pre-treatment of
cells with pertussis toxin (PTX, 1 mg/mL) for 18 h had no
significant effect on HDL- and S1P-induced Stat3 serine and
tyrosine phosphorylation (Figure 3D).
Thus our results indicate that HDL and S1P induce
PTX-insensitive Stat3 phosphorylation essentially through
the receptor S1P2, although in the case of HDL, a possible
involvement of another receptor, with a lesser impact,
cannot be excluded.
3.4 ERK1/2, but neither p38 MAPK nor PI3K, plays a
role in HDL- and sphingosine-1-phosphate-induced
Stat3 activation
Since ERK1/2 and p38 MAPK can act as modulators of Stat3
activation, we studied their role in the activation of Stat3
induced by HDL or S1P in ventricular cardiomyocytes. We
first investigated the effect of HDL and S1P on the phos-
phorylation of ERK1/2 and p38 MAPK. As shown in
Figure 4A, HDL induced a rapid and important phosphoryl-
ation of ERK1/2 and p38 MAPK with significant responses
observed after 5 min. The ERK1/2 phosphorylation level
remained constant during 2 h of exposition to HDL,
whereas that of p38 MAPK decreased slowly after 10 min
of stimulation. However, both ERK1/2 and p38 MAPK phos-
phorylation levels were still increased after 6 h of
Figure 2 Activation of Stat3 by HDL, rHDL, and S1P. Cardiomyocytes were untreated (control) or stimulated for 90 min with HDL (400 mg/mL), S1P (1 or 5 mM) or
three different rHDL containing S1P (rHDL A), S1PþapoAI (rHDL B), or apoAI (rHDL C). (A) Cells were incubated with two concentrations of rHDL: 1 mM S1P and/or
20 mg/mL apoAI (1), and 5 mM S1P and/or 100 mg/mL apoAI (5). Stat3 phosphorylation on tyrosine 705 (Stat3-tyr-P) and serine 727 (Stat3-ser-P) was detected by
western blotting; protein loading was assessed by total Stat3. Specific bands corresponding to phosphorylated Stat3 were quantified by densitometry and
expressed as percentage of the control. *P , 0.05 compared with control values, †P, 0.05 vs. rHDL A and rHDL B, þP , 0.05 vs. rHDL A (n ¼ 3). (B) Cardiomyo-
cytes were stimulated with the three rHDL containing 1 mM S1P and/or 20 mg/mL apoAI. DNA-binding of Stat3 was analysed in nuclear extracts by electrophoretic
mobility shift assay using labelled SIE DNA. To determine Stat3 specific DNA-binding, antibodies against Stat3 and Stat1 were used. The specificity of the labelled
DNA probe was confirmed by competition assay using a 100-fold excess of unlabeled SIE DNA (cold probe). The figure shows a representative example from three
experiments.
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Figure 3 HDL and S1P induce Stat3 phosphorylation through S1P2. Cardiomyocytes were untreated (ctrl) or incubated with S1P antagonists or pertussis toxin,
prior to stimulation for 90 min with S1P (1 mM), S1P agonists (0.1–10 mM), or HDL (400 mg/mL). Stat3 phosphorylation (Stat3-P) was analysed by western blotting
as illustrated by representative western blots. Equal gel loading were assessed by total Stat3. Specific bands corresponding to phosphorylated Stat3 were quan-
tified by densitometry and expressed as percentage of the corresponding control. *P, 0.05 compared with control values, †P, 0.05 vs. S1P or HDL (n ¼ 4–6). (A)
Cells were incubated for 20 min with the specific S1P2 antagonist, JTE013 (JTE, 1 and 5 mM) prior to stimulation with S1P or HDL (n ¼ 6). (B) Cardiomyocytes were
stimulated for 90 min with 0.1 and 1 mM of S1P, the S1P1-specific receptor agonist SEW2871 (SEW) or the high-affinity agonist of S1P1, S1P3, S1P4, and S1P5
receptors, FTY720 (FTY) (n ¼ 4). (C) Cells were treated for 20 min with the selective S1P1/S1P3 antagonist, VPC23019 (VPC, 1 and 5 mM) prior to stimulation
with S1P or HDL (n ¼ 6). (D) Cardiomyocytes were incubated for 18 h with pertussis toxin (PTX, 1 mg/mL) prior to stimulation with S1P or HDL (n ¼ 4).
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stimulation with HDL. The kinetics of S1P-induced ERK1/2
and p38 MAPK phosphorylation was very similar to those of
HDL-induced responses (data not shown).
As for Stat3 phosphorylation, the rHDLs containing S1P (rHDL
A and rHDL B) induced a degree of phosphorylation of ERK1/2
and p38 MAPK similar to S1P alone, whereas rHDL C containing
no S1P elicited a much weaker response (see Figure 4B).
Experiments with agonists and antagonists of S1P receptor
subtypes indicate that, as for Stat3 activation, HDL and S1P
activate ERK1/2 and p38 MAPKmainly through the S1P2 recep-
tor (Figure 5). Indeed, the S1P2 receptor antagonist JTE013
significantly reduced Stat3 ERK1/2 and p38 MAPK phosphoryl-
ation induced by S1P or HDL (Figure 5A). In contrast, SEW2871
(S1P1 receptor agonist) and FTY720 (S1P1, S1P3, S1P4, S1P5
receptor agonist) had only a weak, non-significant effect on
HDL- and S1P-induced ERK1/2 and p38 MAPK phosphorylation
(Figure 5B). Similarly, the S1P1/S1P3 receptor antagonist
VPC23019 did not significantly affect HDL- and S1P-induced
phosphorylation of these kinases (Figure 5C).
To investigate the involvement of p38 MAPK and the ERK1/2
cascade in HDL- and S1P-induced Stat3 activation, we deter-
mined Stat3 phosphorylation and Stat3 DNA-binding after
90 min of stimulation with HDL or S1P in the presence and
absence of their respective inhibitors,21 SB203580 and
U0126. As shown in Figure 6A, blocking the ERK1/2 signalling
pathway with U0126 (10 mM), strongly reduced the HDL- and
S1P-induced serine and tyrosine phosphorylation of Stat3,
whereas inhibiting p38 MAPK with SB203580 (10 mM), had
no significant effect. As for Stat3 phosphorylation, HDL
and S1P-induced Stat3 DNA-binding was essentially sup-
pressed by U0126 while it was only slightly affected by
SB203580 (data not shown). Similarly, inhibition of PI3K by
LY294002 had no effect on HDL- and S1P-induced Stat3 phos-
phorylation, neither on tyrosine nor on serine (Figure 6B).
Both these inhibitors are active in our cellular model,
since we observed that LY294002 abolished leukemia
inhibitory factor-induced phosphorylation of Akt in ventricu-
lar cardiomyocytes, while SB203580 inhibited HDL- and
S1P-induced cyclooxygenase-2 expression (data not shown).
Our results indicate that ERK1/2 is involved in the Stat3
activation promoted by HDL or S1P, but neither p38 MAPK
nor PI3K plays a role.
3.5 Rho-associated kinase and phospholipase
C are involved in HDL- and
sphingosine-1-phosphate-induced ERK1/2
and Stat3 phosphorylation
To clarify how HDL and S1P induce the activation of
ERK1/2 and thus of Stat3, we pharmacologically inhibited
ROCK, PLC, and PKC. In ventricular cardiomyocytes, the
respective inhibitors of ROCK (Y27632,21 10 mM) and PLC
Figure 4 HDL, rHDL, and S1P induce ERK1/2 and p38 MAPK phosphorylation. (A) Cardiomyocytes were untreated (control) or stimulated with HDL (H, 400 mg/
mL) during different time periods (5 min–6 h). (B) Cells were stimulated with the three rHDL containing 1 mM S1P and/or 20 mg/mL apoAI. Cells were also exposed
to S1P (1 mM) and native HDL (400 mg/mL). (A and B) Phosphorylation of ERK1/2 (ERK1/2-P) and p38 MAPK (p38 MAPK-P) was analysed by western blotting, and
protein loading was determined by total p38 MAPK. Specific bands corresponding to the phosphorylated forms of ERK1/2 and p38 MAPK were quantified by densi-
tometry and expressed as percentage of the corresponding control. *P , 0.05 compared with control values, †P, 0.05 vs. rHDL A and rHDL B (n ¼ 3–4).
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Figure 5 HDL and S1P induce ERK1/2 and p38 MAPK phosphorylation through S1P2. Cardiomyocytes were untreated (ctrl) or incubated with S1P antagonists,
prior to stimulation for 90 min with S1P (1 mM), S1P agonists (0.1–10 mM), or HDL (400 mg/mL). ERK1/2 and p38 MAPK phosphorylation (ERK1/2-P and p38
MAPK-P) was analysed by western blotting, as illustrated by representative western blots. Equal gel loading were assessed by total p38 MAPK. Specific bands
corresponding to phosphorylated ERK1/2 and p38 MAPK were quantified by densitometry and expressed as percentage of the corresponding control. *P , 0.05
compared with control values, †P , 0.05 vs. S1P or HDL (n ¼ 4). (A) Prior to stimulation with S1P or HDL, cells were treated for 20 min with 1 and 5 mM of
the S1P2 antagonist JTE013 (JTE). (B) Cardiomyocytes were stimulated with 0.1 and 1 mM of S1P, SEW2871 (SEW, S1P1 receptor agonist), or FTY720 (FTY,
S1P1, S1P3, S1P4, S1P5 receptor agonist). (C) Prior to stimulation with S1P or HDL, cells were treated for 20 min with 1 and 5 mM of the S1P1/S1P3 antagonist,
VPC23019 (VPC).
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Figure 6 HDL- and S1P-induced Stat3 activation is inhibited by U0126 and PP1 but not by SB203580 or LY294002. Cardiomyocytes were untreated (ctrl) or incubated
with various signalling pathway inhibitors orwith protein synthesis inhibitors, prior to stimulation for 90 minwith S1P (1 mM)orHDL (400 mg/mL).Westernblots: Specific
bands corresponding to phosphorylated Stat3 were quantified by densitometry and expressed as percentage of the corresponding control. Equal gel loading were
assessed by total Stat3. *P, 0.05 compared with control values, †P, 0.05 vs. S1P or HDL (n ¼ 4). (A) Cells were left untreated (ctrl) or incubated for 30 min with
10 mM of U0126 (U0) or SB203580 (SB), the inhibitors of ERK1/2 and p38 MAPK, respectively, prior to stimulation with HDL or S1P. (B) Cells were incubated for 1 h
with 10 mMand 20 mM LY294002 (LY), the inhibitor of PI3K, prior to stimulation with S1Por HDL. (C) Cells were incubated for 20 min, with the translation inhibitor cyclo-
heximide (CHX, 10 mg/mL) or the transcription inhibitor actinomycin D (Actino D, 2.5 mg/mL) prior to stimulation with S1Por HDL. (D) Cells were incubated for 1 h with
10 mM and 20 mM of PP1, the inhibitor of Src, prior to stimulation with S1P or HDL.
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(U73122, 2 mM) both partially reduced HDL and S1P-induced
ERK1/2 phosphorylation as well as that of Stat3 on serine
and tyrosine (see Supplementary material online, Figures
S1 and S2). In contrast, the PKC inhibitor Ro-31822021
(1 mM) had no effect on the HDL and S1P-induced phos-
phorylation of ERK1/2 and Stat3 serine but partially inhib-
ited that of Stat3 tyrosine (see Supplementary material
online, Figure S3). Our results suggest the partial involve-
ment of ROCK and PLC, but not PKC, in the activation of
ERK1/2 induced by HDL and S1P.
3.6 Src is involved in HDL- and
sphingosine-1-phosphate-induced tyrosine
phosphorylation of Stat3
Having observed that HDL- and S1P-induced Stat3 tyrosine
phosphorylation and Stat3 DNA-binding is delayed, mainly
occurring after 60 min of stimulation, we hypothesized that
newly synthesized proteins are necessary for Stat3 activation.
Therefore, we blocked translation and transcription with
cycloheximide and actinomycin D, respectively. As illustrated
in Figure 6C, both inhibitors abolished HDL and S1P-induced
Stat3 phosphorylation on tyrosine without affecting that on
serine. Similarly, inhibition of the tyrosine kinase family Src
with PP121 abolished Stat3 phosphorylation on tyrosine pro-
moted by S1P and caused 70% reduction of the HDL-induced
Stat3 phosphorylation. In contrast, PP1, had no effect on
serine phosphorylation of Stat3 (Figure 6D). These findings
were confirmed by experiments using the Src tyrosine kinase
inhibitor 1 (see Supplementary material online, Figure S4A).
Consistently, HDL and S1P were both found to induce a signifi-
cant, transient increase in Src phosphorylation after 1 h of
stimulation (see Supplementary material online, Figure S4B).
Our results indicate that newly synthesized protein(s) are
necessary for HDL- and S1P-induced Stat3 activation and
that tyrosine kinase family Src is involved in the tyrosine
phosphorylation of Stat3.
4. Discussion
Our data show, for the first time to our knowledge, that HDL
induces the activation of Stat3, and attribute a predominant
role to S1P. Stat3 activation, as characterized by increased
tyrosine phosphorylation and DNA-binding activity after
stimulation of ventricular cardiomyocytes with HDL, was
delayed when compared with cytokine-induced activation
of Stat3 which is known to occur very rapidly in various
cell types. In contrast, Stat3 phosphorylation on serine resi-
dues, which has been reported to play a modulatory role in
the activation of Stat3,12,13 occurred very rapidly after
stimulation with HDL or S1P.
S1P and rHDLs containing S1P had a strong stimulatory
action on Stat3, ERK1/2, and p38 MAPK, comparable to
HDL isolated from human plasma. In contrast, rHDL contain-
ing apoAI but no S1P had a much weaker effect, indicating
that HDL-induced activation of Stat3, ERK1/2, and p38
MAPK occurs mainly through its S1P component. Confirming
this hypothesis, the stimulatory effects of rHDL containing
S1P and apoAI were not significantly different from those
of rHDL containing only S1P. In this context, it is important
to note that rHDL containing S1P and apoAI could lead to
an increased cardioprotection by two different mechanisms.
On the one hand, S1P and S1P-containing rHDL were found to
activate potent intracellular signalling pathways being
involved in cardiac remodelling.2,8 On the other hand,
apoAI and mimetic peptides have been shown to influence
reverse cholesterol transport and reduce atherosclerosis
in mice.22
Extracellular S1P acts by binding to plasma membrane G
protein-coupled receptors identified as S1P1, S1P2, S1P3,
S1P4, and S1P5. To date the S1P receptor subtypes that
have been found to play a functional role in the cardiovascu-
lar system are S1P1, S1P2, and S1P3.23 Using various agonists
and antagonists of the G-protein-coupled S1P receptor sub-
types S1P1–S1P5, including two potent and specific inhibi-
tors of S1P1/S1P3 and S1P2, respectively, we found that
S1P and HDL activate Stat3 mainly through the S1P2 recep-
tor. In the case of HDL, the involvement of another receptor,
possibly activated through the apoAI component of HDL
cannot be excluded. The observation that HDL and
S1P-induced Stat3 activation was not affected by PTX
suggests the involvement of a PTX-insensitive G protein
such as G12/13, which has been shown to be coupled to
the S1P2 receptor.18 At the present time, there are few
studies concerning the role of S1P receptors in cardiomyo-
cytes. Robert et al.24 reported that S1P induces cardiomyo-
cyte hypertrophy mainly via the S1P1 receptor and
subsequently via Gi through ERK1/2, p38 MAPK, PI3K, and
via Rho pathways. Similarly, the protective effect of S1P
during hypoxia in ventricular cardiomyocytes was found to
require activation of the S1P1 receptor and the
PTX-sensitive Gi protein.
19 In contrast, Theilmeier et al.8
found that HDL and its constituent S1P protects the heart
against I/R injury in vivo via an S1P3 receptor-mediated
and NO-dependent pathway. In the same context, Means
et al.25 reported that both S1P2 and S1P3 receptors contrib-
ute to protect cardiomyocytes from I/R damage in vivo, and
that the protective effect of S1P released in response to I/R
involves receptor-mediated Akt activation. Clearly, further
studies are necessary to elucidate whether in cardiac myo-
cytes, S1P1, S1P2, and S1P3 receptors regulate different sig-
nalling pathways associated with specific functions.
The observation that HDL induces Stat3 activation in ven-
tricular cardiomyocytes could be of clinical interest since
there is increasing evidence that Stat3 is beneficial for the
heart. Indeed, Stat3 appears to play diverse important roles
in myocardium adaptation to stress; by maintaining
myocardial capillarization, controlling interstitial collagen
metabolism, protecting from apoptosis, and preserving
cardiac function.9,10 Conditional knockout mice harboring a
cardiomyocyte-restricted deletion of Stat3 showed increased
susceptibility to cardiac injury caused by myocardial ischae-
mia, inflammation, or drug toxicity.9,26 Stat3 has also been
shown to provide cardioprotection from the anti-tumour
drug doxorubicin.26,27 Moreover, it appears that Stat3 acti-
vation confers cardioprotection at the time of reperfusion
in response to TNF-a and ischaemic preconditioning.28,29
There are two studies reporting a negative effect of HDL on
Stat3 activation. Parhami et al.30 found that exposure
of osteoblast-like vascular cells to HDL for 24 h had no effect
on the basal Stat3 phosphorylation level but partially inhibited
interleukin-6-induced Stat3 phosphorylation. Similarly,
Gharavi et al.31 observed that in human aortic endothelial
cells, HDL significantly reduced Stat3 tyrosine phosphorylation
induced by oxidized 1-palmotyl-2-arachidonyl-sn-3-glycero-
phosphorylcholine within 5 min while it had no effect on
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basal Stat3 phosphorylation. These observations are not
necessarily inconsistent with our results since we found that
shorter time periods of exposition to HDL (3–30 min) resulted
in a slight decrease in Stat3 tyrosine phosphorylation and that
5 min of stimulation had no effect on Stat3 DNA-binding.
Indeed, we observed that HDL-induced Stat3 tyrosine phos-
phorylation and Stat3 DNA-binding is delayed, mainly occur-
ring after 60–90 min of stimulation.
Our study revealed a role for ERK1/2 in HDL- and
S1P-induced Stat3 activation. Indeed, inhibition of ERK1/2
but not of p38 MAPK or of PI3K abolished HDL-induced
Stat3 activation. Consistent with these results, we have pre-
viously shown that ERK1/2 activation is a necessary event
for prostaglandin E2-induced Stat3 activation in ventricular
cardiomyocytes.14
The mechanism leading to the activation of ERK1/2
appears to be complex. Our findings indicate that ROCK
and PLC but not PKC, account for at least part of the HDL
and S1P-induced activation of ERK1/2. However, further
studies are necessary to elucidate all the steps and crosstalk
of the signalling cascades playing a role in the ERK1/2 acti-
vation in HDL-stimulated cardiomyocytes.
Blocking translation with cycloheximide showed that
ERK1/2 plays an indirect role in the delayed tyrosine phos-
phorylation of Stat3 induced by HDL and S1P. Indeed, our
results indicate that HDL and S1P-induced Stat3 activation
requires newly synthesized protein(s), which could be or
induce a non-receptor tyrosine-kinase. In agreement with
this hypothesis, we found that in ventricular cardiomyocytes
exposed to HDL or S1P for 90 min, the Src inhibitors PP1 and
Src inhibitor 1 strongly reduced Stat3 phosphorylation on
tyrosine but not on serine. These findings suggest that
newly synthesized Src could play a role in HDL and
S1P-induced Stat3 activation. However, at the present
time, we cannot exclude that newly synthesized protein(s)
could be released and act in an autocrinemanner to stimulate
a receptor-associated tyrosine kinase as shown for angioten-
sin II inducing Stat3 tyrosine phosphorylation through the
autocrine action of secreted IL-6 family cytokines.32
Further investigations are needed to elucidate the different
steps involved in the delayed activation of Stat3 by HDL.
In summary, the present study demonstrates that in ven-
tricular cardiomyocytes, HDL induces Stat3 activation
mainly via its S1P constituent and the receptor S1P2. More-
over, we provide evidence for the involvement of ERK1/2
and Src in HDL-induced Stat3 activation. Our studies
further indicate that ROCK and PLC are involved in the acti-
vation of ERK1/2 induced by HDL. These findings are in
agreement with those of Hu et al.,33 reporting that in
smooth muscle, SIP2 but not S1P1 receptors activate PLC-b
and ROCK. The fact that rHDL containing S1P has the same
effects as native HDL on Stat3 and ERK1/2, both known to
play a role in cardiac remodelling, underlines the potential
significance of modulating rHDL composition. The latter
opens new perspectives of therapeutic strategies with
rHDL tailored to confront particular pathological situations
and offering increased cardioprotection.
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